Literature DB >> 21274376

A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma.

Yuzhu Jiang1, Seon-Hee Yim, Hai-Dong Xu, Seung-Hyun Jung, So Young Yang, Hae-Jin Hu, Chan-Kwon Jung, Yeun-Jun Chung.   

Abstract

AIM: To explore the expression pattern of E2F5 in primary hepatocellular carcinomas (HCCs) and elucidate the roles of E2F5 in hepatocarcinogenesis.
METHODS: E2F5 expression was analyzed in 120 primary HCCs and 29 normal liver tissues by immunohistochemistry analysis. E2F5-small interfering RNA was transfected into HepG2, an E2F5-overexpressed HCC cell line. After E2F5 knockdown, cell growth capacity and migrating potential were examined.
RESULTS: E2F5 was significantly overexpressed in primary HCCs compared with normal liver tissues (P = 0.008). The E2F5-silenced cells showed significantly reduced proliferation (P = 0.004). On the colony formation and soft agar assays, the number of colonies was significantly reduced in E2F5-silenced cells (P = 0.004 and P = 0.009, respectively). E2F5 knockdown resulted in the accumulation of G0/G1 phase cells and a reduction of S phase cells. The number of migrating/invading cells was also reduced after E2F5 knockdown (P = 0.021).
CONCLUSION: To our knowledge, this is the first evidence that E2F5 is commonly overexpressed in primary HCC and that E2F5 knockdown significantly repressed the growth of HCC cells.

Entities:  

Keywords:  E2F family; E2F5; Hepatocellular carcinoma; Oncogene; Small interfering RNA

Mesh:

Substances:

Year:  2011        PMID: 21274376      PMCID: PMC3027013          DOI: 10.3748/wjg.v17.i4.470

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

1.  Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma.

Authors:  B Eymin; S Gazzeri; C Brambilla; E Brambilla
Journal:  Oncogene       Date:  2001-03-29       Impact factor: 9.867

2.  E2F4 loss suppresses tumorigenesis in Rb mutant mice.

Authors:  Eunice Y Lee; Hieu Cam; Ulrike Ziebold; Joseph B Rayman; Jacqueline A Lees; Brian David Dynlacht
Journal:  Cancer Cell       Date:  2002-12       Impact factor: 31.743

3.  Genetic analysis of early- versus late-stage ovarian tumors.

Authors:  V Shridhar; J Lee; A Pandita; S Iturria; R Avula; J Staub; M Morrissey; E Calhoun; A Sen; K Kalli; G Keeney; P Roche; W Cliby; K Lu; R Schmandt; G B Mills; R C Bast; C D James; F J Couch; L C Hartmann; J Lillie; D I Smith
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

4.  Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors.

Authors:  J Polanowska; L Le Cam; B Orsetti; H Vallés; E Fabbrizio; L Fajas; S Taviaux; C Theillet; C Sardet
Journal:  Genes Chromosomes Cancer       Date:  2000-05       Impact factor: 5.006

5.  E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints.

Authors:  Bing Ren; Hieu Cam; Yasuhiko Takahashi; Thomas Volkert; Jolyon Terragni; Richard A Young; Brian David Dynlacht
Journal:  Genes Dev       Date:  2002-01-15       Impact factor: 11.361

6.  Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.

Authors:  G Peter Sawiris; Cheryl A Sherman-Baust; Kevin G Becker; Chris Cheadle; Diane Teichberg; Patrice J Morin
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

7.  Identification of twenty-two candidate markers for human osteogenic sarcoma.

Authors:  B Fuchs; K Zhang; A Schabel; M E Bolander; G Sarkar
Journal:  Gene       Date:  2001-10-31       Impact factor: 3.688

Review 8.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

9.  E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.

Authors:  Narasimhan Kothandaraman; Vladimir B Bajic; Pang N K Brendan; Chan Y Huak; Peh B Keow; Khalil Razvi; Manuel Salto-Tellez; Mahesh Choolani
Journal:  BMC Cancer       Date:  2010-02-24       Impact factor: 4.430

10.  E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide.

Authors:  Sehwan Han; Kyeongmee Park; Byung-Noe Bae; Ki Hwan Kim; Hong-Joo Kim; Young-Duck Kim; Hong-Yong Kim
Journal:  Breast Cancer Res Treat       Date:  2003-11       Impact factor: 4.872

View more
  19 in total

1.  An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates.

Authors:  Bhavneet Bhinder; Christophe Antczak; Christina N Ramirez; David Shum; Nancy Liu-Sullivan; Constantin Radu; Mark G Frattini; Hakim Djaballah
Journal:  Assay Drug Dev Technol       Date:  2012-11-30       Impact factor: 1.738

2.  Transcriptional E2F1/2/3/6 as potential prognostic biomarkers in cutaneous melanoma.

Authors:  Jing Li; Xiao-Lei Shu; Qing Shao; Qian Luo; Qing-Chun Diao; Xin Zhang; Jiang-Dong Sui; Jing Guo; Dan Tao; Xian Zhou; Ying Wang; Can Wang
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

3.  E2F transcription factors and digestive system malignancies: how much do we know?

Authors:  Konstantinos Evangelou; Sophia Havaki; Athanassios Kotsinas
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  miRNA-34a enhances the sensitivity of gastric cancer cells to treatment with paclitaxel by targeting E2F5.

Authors:  Lina Li; Cuiling Wu; Yue Zhao
Journal:  Oncol Lett       Date:  2017-04-18       Impact factor: 2.967

5.  Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.

Authors:  Daniele Baiz; Barbara Dapas; Rossella Farra; Bruna Scaggiante; Gabriele Pozzato; Fabrizio Zanconati; Nicola Fiotti; Lara Consoloni; Sara Chiaretti; Gabriele Grassi
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

6.  Walleye dermal sarcoma virus: expression of a full-length clone or the rv-cyclin (orf a) gene is cytopathic to the host and human tumor cells.

Authors:  Kun Xu; Ting Ting Zhang; Ling Wang; Cun Fang Zhang; Long Zhang; Li Xia Ma; Ying Xin; Chong Hua Ren; Zhi Qiang Zhang; Qiang Yan; Daniel Martineau; Zhi Ying Zhang
Journal:  Mol Biol Rep       Date:  2012-10-26       Impact factor: 2.316

7.  Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer.

Authors:  Huijun Xie; Xiaoli Ren; Sainan Xin; Xiaoliang Lan; Guifeng Lu; Yuan Lin; Shaoshan Yang; Zhicheng Zeng; Wenting Liao; Yan-Qing Ding; Li Liang
Journal:  Oncotarget       Date:  2016-05-03

8.  An integrative meta-analysis of microRNAs in hepatocellular carcinoma.

Authors:  Mahmoud ElHefnawi; Bangli Soliman; Nourhan Abu-Shahba; Marwa Amer
Journal:  Genomics Proteomics Bioinformatics       Date:  2013-11-25       Impact factor: 7.691

9.  The transcription factor FOXN3 inhibits cell proliferation by downregulating E2F5 expression in hepatocellular carcinoma cells.

Authors:  Ji Sun; Hong Li; Qi Huo; Meiling Cui; Chao Ge; Fangyu Zhao; Hua Tian; Taoyang Chen; Ming Yao; Jinjun Li
Journal:  Oncotarget       Date:  2016-07-12

10.  Prognostic Values of E2F1/2 Transcriptional Expressions in Chromophobe Renal Cell Carcinoma Patients: Evidence from Bioinformatics Analysis.

Authors:  Dingtao Hu; Nana Meng; Xiaoqi Lou; Zhen Li; Ying Teng; Bizhi Tu; Yanfeng Zou; Fang Wang
Journal:  Int J Gen Med       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.